Fagron Sa · EURONEXT:FAGR
Fagron Sa — Fagron Sa Ord — Q3 2022 Earnings Presentation
9 slides from Fagron Sa's earnings presentation, Oct 13, 2022
Slide 1: 9M 2022 Trading Update
9M 2022 Trading Update 13 October 2022 Rafael Padilla Karin De Jong CEO CFO
Slide 2: Disclaimer
Disclaimer The contents of this document, including all statements made therein, are based on estimates, assumptions and other information currently available to the management of Fagron. Certain statements in this presentation may be deemed to be forward-looking. Such forward-looking statements are
Slide 3: Resilient revenue performance in increasingly uncertain environment
Resilient revenue performance in increasingly uncertain environment Total revenue growth of 19.7% and organic growth at CER of 5.1% in 9M 2022 9M Total Q3 Total Revenue Revenue €173.0m €501.5m Challenging macro economic developments to various degrees across all markets 9M Reported Q3 Reported growt
Slide 4: Revenue growth supported by EMEA, FX and M&A
Revenue growth supported by EMEA, FX and M&A Revenue Bridge (€ m) 34.0 500,0 39.6 11.6 450,0 13.8 4.0 2.8 400,0 350,0 501.5 300,0 418.9 250,0 200,0 9M 2021 EMEA Latin America North America Acquisitions FX Divestment 9M 2022 EMEA Latin America North America 50,0 43.0 70,0 64.9 80,0 65.1 45,0 36.8 70,
Slide 5: Driving operational efficiencies and protecting leading positions
Driving operational efficiencies and protecting leading positions Global Continued supply chain & Continued globalization of Committed to set science-based Geraldino Neder inflationary pressure procurement function emission reduction targets as part of appointed as Latin America Area our sustainabil
Slide 6: Ensuring compliance with increased regulatory standards
Ensuring compliance with increased regulatory standards FDA audit process St. Paul Facility (repackaging) • FDA inspection conducted in November 2021 • Warning Letter issued by FDA in June 2022 • Monthly progress reports submitted with FDA ~2 years • FDA issues warning letter close-out letter on sat
Slide 7: Global leader in niche pharmaceutical compounding market
Global leader in niche pharmaceutical compounding market Favorable secular trends Resilient business model • Demographics • Strong revenue growth • Personalization • Attractive margins • Accessibility • Diversified geographical presence • Regulation • Broad product portfolio • Market fragmentation •
Slide 8: Full year 2022 outlook maintained
Full year 2022 outlook maintained H1 2022 Guidance FY 2022 Revenue* €328.6m €670m – €690m REBITDA margin* 19.3% H2 margin higher than H1 Capex as a % of revenue 2% 3 – 3.5% * Excluding the impact of 503B facility in Boston
Slide 9: Questions
Questions